The treatment of multiple sclerosis (MS) has changed over the last 20 years. All
immunotherapeutic drugs target relapsing remitting MS (RRMS) and it still remains a …

Multiple sclerosis (MS) is an immune-inflammatory disease that attacks and damages
myelinated axons in the central nervous system (CNS) and causes nontraumatic …

Tanshinones, lipophilic diterpenes isolated from the rhizome of Salvia miltiorrhiza, have
diverse pharmacological activities against human ailments including neurological diseases …

With evolving diagnostic criteria and the advent of new oral and parenteral therapies for MS,
most current diagnostic and treatment algorithms need revision and updating. The diagnosis …

Background Markerless motion capture has the potential to perform movement analysis with
reduced data collection and processing time compared to marker-based methods. This …

Multiple sclerosis (MS) is a multifactorial, immune-mediated disease caused by complex
gene-environment interactions. Dietary factors modulating the inflammatory status through …

Multiple sclerosis (MS) is a progressive neurological disorder characterized by both
inflammatory and degenerative components that affect genetically susceptible individuals …

Abstract Recombinant interferon (IFN) β-1b was approved by the US Food and Drug
Administration as the first disease-modifying therapy (DMT) for multiple sclerosis (MS) in …

Magnetic resonance imaging (MRI) is a fundamental tool in the diagnosis and management
of neurological diseases such as multiple sclerosis (MS). New portable, low-field strength …

The cytokines IL-6 and IL-10 are produced by cells of the adaptive and innate arms of the
immune system and they appear to play key roles in genetically diverse autoimmune …